BRKR Stock Recent News

Bruker (BRKR) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Bruker's (BRKR) NANO Life Science fluorescence microscopy is gaining from product innovation and research demand.

Bruker (BRKR) completes the installation of its 1.2 (GHz) Avance nuclear magnetic resonance (NMR) spectrometer at the Leibniz Forschungsinstitut f??r Molekulare Pharmakologie in Berlin.

Bruker's (BRKR) NANO Life Science fluorescence microscopy is gaining from product innovation and research demand, further bolstered by the addition of Inscopix's neuroscience research tools.

BOSTON--(BUSINESS WIRE)--Cellens, Inc., an early-stage cancer diagnostic company pioneering in applying mechanobiology and machine learning analysis today announced that it is collaborating with Bruker BioAFM, a business unit of Bruker (Nasdaq: BRKR), to develop the world's first clinical diagnostic tests that leverage multi-parametric, single-cell biophysical markers and machine learning. Based on cellular biophysical markers attained using Bruker's advanced atomic force microscopy, Cellens is.

Bruker's (BRKR) neofleX is a versatile, high-performance and easy-to-use multiomics MSI system for biopharma, translational and clinical researchers.

ANAHEIM, Calif.--(BUSINESS WIRE)---- $BRKR #BRKR--At the 72nd ASMS meeting, Bruker Corporation (Nasdaq: BRKR) launches the new top-of-the-line timsTOF Ultra 2 system with significantly further enhanced sensitivity for deep profiling of small cells, subcellular organelles, as well as increased sample loading flexibility. Together with new Spectronaut 19 software and the novel PreOmics ENRICHplus kit, Bruker is setting new 4D-Proteomics standards from highest sensitivity to large-scale, deep plasma proteomics. B.

ANAHEIM, Calif.--(BUSINESS WIRE)---- $BRKR #BRKR--The Bruker Applied Mass Spectrometry Division is showcasing some of its latest innovations at ASMS 2024: New EVOQ® DART-TQ+ system for chromatography-free triple-quadrupole mass spectrometry for point-of-need (PoN) routine analysis Launch of novel ecTOF™ with simultaneous EI and CI ionization in TOF high-resolution mass spectrometry, for ultimate confidence in compound identification with GC-HRMS Innovative Applied Markets Solutions The new EVOQ DART-TQ⁺ mass s.

BILLERICA, Mass.--(BUSINESS WIRE)---- $BRKR #BRKR--Bruker Corporation (Nasdaq: BRKR) announced today it will present at the following conferences: 2024 Jefferies Global Healthcare Conference, New York, NY Thursday, June 6, 2024, at 7:30 a.m. Eastern Time Frank Laukien, Chairman, President and Chief Executive Officer Juergen Srega, President, Bruker CALID Group 45th Annual Goldman Sachs Global Healthcare Conference, Miami, FL Wednesday, June 12, 2024, at 11:20 a.m. Eastern Time Gerald Herman, Executive Vice Pre.

BILLERICA, Mass.--(BUSINESS WIRE)---- $BRKR #BRKR--Bruker Corporation (“Bruker” or the “Company”) (Nasdaq: BRKR) today announced the pricing of its previously announced underwritten registered public offering of 6,000,000 shares of its common stock. Additionally, the Company has granted the underwriters a 30-day option to purchase up to an additional 900,000 shares of its common stock. The offering is expected to close on or about May 31, 2024, subject to market and other customary closing conditions. Bruker i.